PO-1332 Risk factors for intracranial metastasis in stage III NSCLC after chemoradiation

S. N. Thibodeau; M. Meem; Shahneen Sandhu; W. Hopman; Geneviève C. Digby; Saeed Alghamdi; T. Owen; A. Ashworth; Andrea S. Fung; Adi Kartolo; Andrew Robinson; Osbert C. Zalay; Fábio Ynoe de Moraes

doi:10.1016/s0167-8140(23)66247-4

Related publications

Article2024

Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT).

Michael A. Davies, Julie M. Simon, Alexander M. Menzies, Denái R. Milton, James S. Wilmott, Debora Alejandra Ledesma, Elizabeth M. Burton, Sherise D. Ferguson, Hussein A. Tawbi, Jeffrey E. Gershenwald, Carlos A. Torres‐Cabala, Isabella Claudia Glitza, Alexander J. Lazar, Robyn P.M. Saw, Andrew J. Spillane, Matteo S. Carlino, Richard A Scolyer, Georgina V. Long

Article2019

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8TH EDITION STAGE III MELANOMA PATIENTS

Lauren E. Haydu, Serigne Lo, Jennifer L. McQuade, Isabella C. Glitza, Hussein A. Tawbi, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Alexander J. Lazar, Michael T. Tetzlaff, Richard A Scolyer, Jeffrey E. Gershenwald, John F. Thompson, Michael A. Davies

Article2013

Clinical characteristics and risk factors of intracranial hemorrhage in systemic lupus erythematosus

Na Gao, Zhong Lin Wang, MT Li, Han Sm, YQ Dang, FC Zhang, Shi Ty, LN Zhang, Zeng Xf

Article2025

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Andrea Boutros, Amelia M. Taylor, Isabel Li, Nurudeen A. Adegoke, Terence Z. Wong, Alexander H. R. Varey, Kerwin F. Shannon, Sydney Ch'ng, R.P.M. Saw, Thomas E. Pennington, Jonathan R. Stretch, Andrew J. Spillane, Alexander C.J. van Akkooi, Richard A Scolyer, Inês Pires da Silva, Matteo S. Carlino, Georgina V. Long, Serigne Lo, Alexander M Menzies

Article2019

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

Irene L. M. Reijers, Elisa A. Rozeman, Alexander M. Menzies, Bart A. van de Wiel, Hanna Eriksson, Karijn P.M. Suijkerbuijk, Astrid Aplonia Maria Van Der Veldt, Ellen Kapiteijn, Geke A.P. Hospers, W. Martin C. Klop, Andrew J. Spillane, Richard A Scolyer, Inge Marie Svane, Lars Bastholt, Henrik Schmidt, James Larkin, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long, Christian U. Blank